Adaptive Biotech

Launch your next molecular #immuneprofiling study in days — not weeks. Adaptive has partnered with @scientist_com — giving you a faster path from idea to actionable #TCR and #BCR deep sequencing results. Start your project today. adaptivebio.tech/kmp

What happens when models learn directly from large-scale T cell activation data? In one benchmark, a sequence-based approach outperformed structure-based pipelines—while running much faster. adaptivebio.tech/6xq #worldimmunologyday

How do T-cell receptors recognize antigens—and which interactions lead to activation? New work (presented at #ML4H2025) explores a data-driven approach using large-scale T-cell activation data. Read more: adaptivebio.tech/6xq

Adaptive is attending #AACR26. We partner with biopharma teams using T- and B-cell receptor sequencing and MRD testing to advance hematology and oncology research and clinical trials. Let’s talk about your study. 📩 bd@adaptivebiotech.com

ICYMI: Adaptive's latest webinar highlights how our TCR and BCR sequencing technologies and large-scale immune repertoire database can accelerate the development of immune-modulating therapies. 🎧 Access the recording now: adaptivebio.tech/2hj

This #MyelomaAwarenessMonth, hear from Allison Jacob, VP Medical Affairs, how MRD testing is informing care decisions across the myeloma journey. Adaptive is working to help bring better outcomes to people living with lymphoid malignancies.

There’s still time to register for our March 18 webinar ⏰ Learn how immunosequencing and large scale immune data drive smarter R&D decisions—from MoA validation to PK/PD and TCR signal detection. 👉 Register: adaptivebio.tech/dc215c

This #IWD2026, Sr. Dir. R&D Katie Husske reminds us, “each of us has something valuable to contribute—whether it’s our expertise, our time, or simply a willingness to listen.” #GiveToGain #BeAdaptive

March is Myeloma Action Month. 🩸 Taking action starts with awareness. Understanding what remains can change what comes next. #MyelomaActionMonth #MoreThanMyeloma

Last week, we came together to celebrate #BlackHistoryMonth and welcome the #YearoftheHorse with shared traditions, a festive raffle and bake sale. We proudly raised funds to support the William Grose Center for Cultural Innovation in Seattle’s Central District.

New Adaptive research, featured in @DrugDiscovNews, shows how T-cell receptor sequencing can identify shared, celiac-associated immune signatures in blood—highlighting the potential for a noninvasive approach to studying and monitoring celiac disease.🔗 adaptivebio.tech/fth

Join our 3/18 webinar covering our immunosequencing technologies and large-scale database that inform actionable R&D decisions to accelerate the development of immune-modulating therapies. Register: adaptivebio.tech/dc215c

This #BlackHistoryMonth, we recognize Nyabuom Chuol, Senior Clinical Services Specialist, for her leadership within our Black Adapter Network #ERG. Nyabuom strengthens connections, advances inclusion, and helps foster a culture of belonging across our organization. #BeAdaptive

Excited to join experts in HCT, cellular and gene therapy at the 2026 Tandem Meetings of @ASTCT and @CIBMTR! Stop by Booth #108. #Tandem26

We’re proud to be recognized with the Human Rights Campaign Foundation's Equity 100 Award for our commitment to equity and inclusion in the workplace. Read more: adaptivebio.tech/o5h

FDA released draft guidance on the use of MRD as an endpoint to support accelerated approval in multiple myeloma, consistent w/ the 2024 ODAC recommendation. This positive step forward may help bring new therapies to patients and providers more quickly. adaptivebio.tech/ema

We’re excited to kick off the year at #JPM26. CEO Chad Robins will present on Monday, January 12 at 4:30 p.m. PT / 7:30 p.m. ET. A live and archived webcast of the event will be available in the investors section of our website. adaptivebio.tech/qf0

As we close out the year, we’re grateful for the curiosity, collaboration, and innovation that drive our work—and the colleagues and partners who make it possible. #BeAdaptive #HappyNewYear

We’ve now reached 100,000 patients tested with clonoSEQ®. Grateful to the patients and clinicians who trust us in their care journey. Learn more: clonoSEQ.com

Adaptive has entered into two licensing agreements with @Pfizer, leveraging our immune medicine platform and precision immunology data to inform the potential development of immune-based therapeutic products. Learn more: adaptivebio.tech/6qq